Exelixis Has Renewed Momentum Heading Into 2021
The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.
You may also be interested in...
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.
Keeping Track: 2021’s First Novel Approvals Go To HIV And Heart Failure Therapies Opdivo Starts Year With A Bang
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company plans to launch within two weeks, priced at a premium to competing drugs in kidney cancer.